IFN-γ Combined With T Cells in the Treatment of Refractory Malignant Pleural Effusion and Ascites

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

China

Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu